📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 2.7.2 — Summary of Clinical Pharmacology Studies

Field	Value
Document ID	M272
Version	3.0 (submission-grade)
Compound	GLPI-103 (GLP-1/APJ dual agonist)
Sponsor	Virtual Biopharma Inc.
Standard	ICH M4E(R2) §2.7.2 · E7 · M12 · E14 & E14/S7B Q&A · M10
Confidentiality	Confidential

[MOCK — deep-knowledge assumption] This summary synthesizes the clinical-pharmacology program. The underlying individual study reports are the deep-knowledge mock reports CLINPHARM-001 (biopharmaceutics), CLINPHARM-002 (human PK), CLINPHARM-003 (PD & QT), IMMUNO-001 (immunogenicity), and BIOANALYTICAL-001 (assays), and the early-phase CSRs (CSR-101/102/201). Pivotal Phase-3 outcomes cite CSR-301 (outputs/). Parameters cite REF-002.

Change History

Version	Date	Author	Summary of Change
1.0	2026-06-29	Clin Pharm	Initial
2.0	2026-06-29	Clin Pharm	Full — PK params, special populations, E-R, immunogenicity, QT
3.0	2026-07-05	Clin Pharm	Submission-grade — integrated the individual 5.3 study reports; expanded PK, special-population, DDI, E-R, immunogenicity, and E14 sections with cross-references

Abbreviations

ADA anti-drug antibody · AUC area under the curve · Cmax peak concentration · C–QTc concentration–QTc · CYP cytochrome P450 · DDI drug–drug interaction · E–R exposure–response · F absolute bioavailability · popPK population pharmacokinetics · QD once daily · QW once weekly · t½ terminal half-life.

---

1. Background and Scope of the Clinical Pharmacology Program

The clinical-pharmacology package characterizes the absorption, distribution, metabolism, and excretion of GLPI-103; the relationship of exposure to glycaemic efficacy and to gastrointestinal tolerability; the impact of intrinsic and extrinsic factors; immunogenicity; and cardiac (QT) safety. It draws on the first-in-human single- and multiple-ascending-dose studies (GLPI103-101, -102), the Phase 2 dose-finding study (GLPI103-201), dedicated special-population and interaction studies, and population analyses of pooled data. The two clinical formulations — a once-weekly intravenous solution and a once-daily oral tablet enabled by a permeation enhancer — are characterized in parallel because their biopharmaceutics differ fundamentally (M2.7.1; CLINPHARM-001).

2. Pharmacokinetics

Property	Summary [MOCK]	Source
Single dose (101)	approximately dose-proportional exposure; long terminal t½ (~130 h) driven by reversible albumin binding → once-weekly IV	CSR-101; CLINPHARM-002 §2
Multiple dose (102)	modest, predictable accumulation (≈1.4 QW / ≈2.0 QD); steady state by ~4–5 weeks	CSR-102; CLINPHARM-002 §2
Absorption (oral)	permeation-enhancer-mediated; absolute F ≈ 1–2%; strong food/administration-condition dependence	CLINPHARM-001 §2–3
Distribution	low apparent volume; extensive reversible albumin binding	CLINPHARM-002
Metabolism / Excretion	proteolytic catabolism to peptide fragments/amino acids; negligible CYP/transporter involvement	CLINPHARM-002 §5
Variability	moderate-to-high for oral exposure (absorption-driven); characterized in popPK	CLINPHARM-002 §3

Exposure was approximately dose-proportional for both routes across the studied range, and the long half-life supports the once-weekly (IV) and once-daily (oral) regimens with the conservative 8-week titration used in Phase 3 (PROT-301 §6).

3. Pharmacodynamics

GLPI-103 produces dose-dependent GLP-1-pathway effects (glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, reduced appetite) and APJ engagement (plasma-apelin modulation, improved insulin sensitivity), translating into dose-dependent HbA1c and body-weight reductions (CSR-201) and favourable cardiometabolic biomarkers (NT-proBNP, hsCRP) that differentiate the dual agonist from GLP-1-only agents (CLINPHARM-003 §1). Target engagement was evident from the first-in-human studies (plasma apelin, glucose).

4. Exposure–Response

A positive, saturating exposure–response relationship for HbA1c reduction was established across Phase 1b/2 and is consistent with the Phase 3 result, in which the higher-exposure IV arm achieved the larger reduction (LS-mean CFB −2.57% IV vs −2.23% oral; CSR-301 §11.3). A parallel positive exposure–response for gastrointestinal tolerability (nausea) — highest in the IV arm (32.3% vs 21.4% for semaglutide, p=0.003; CSR-301 §12.3) — defined the efficacy–tolerability balance and motivated the titration schedule (CLINPHARM-002 §3; PROT-301 §6).

5. Intrinsic and Extrinsic Factors (Special Populations & DDI)

• Hepatic / renal impairment: because intact GLPI-103 is cleared by proteolytic catabolism rather than hepatic or renal routes, dedicated studies showed ≤1.2–1.3-fold exposure changes and no dose adjustment is required; the Phase 3 eGFR ≥45 floor is consistent with these data (CLINPHARM-002 §4).
• Age / sex / body weight / region: no clinically relevant effect on dose-normalized exposure after allometric weight adjustment; body weight is retained as a popPK covariate (CLINPHARM-002 §3).
• Drug–drug interactions: low perpetrator potential (peptide, negligible CYP); a CYP probe-cocktail study, an oral-contraceptive study, and background metformin showed no clinically relevant interaction. The only consideration is the class-related delayed gastric emptying, which may alter the rate of absorption of sensitive co-administered oral drugs (CLINPHARM-002 §5; M12).

6. Immunogenicity

Treatment-emergent anti-drug antibodies were infrequent, low-titre, transient, and non-neutralizing, with no measurable effect on GLPI-103 exposure, HbA1c response, or safety, and no cross-reactivity with endogenous GLP-1 or apelin. The tiered assays (screening/confirmatory/titre/neutralizing) were validated to fit-for-purpose criteria (IMMUNO-001; BIOANALYTICAL-001 §3).

7. Cardiac Safety (QT/QTc)

Under ICH E14 and the E14/S7B Q&A "double-negative" framework, GLPI-103 did not prolong the QTcF interval to a clinically relevant degree: the upper bound of the 90% CI for ΔΔQTcF was <10 ms at therapeutic and supratherapeutic exposure, the concentration–QTc slope was shallow and non-significant, and assay sensitivity was demonstrated — concordant with the negative nonclinical hERG/telemetry data (M2.4). A modest, expected heart-rate increase typical of the incretin/APJ class was observed without a repolarization signal (CLINPHARM-003 §2; CSR-301 §12.6).

8. Bioanalytical Support

The quantitative PK assay (LC–MS/MS) and the tiered ADA assay were validated to ICH M10 and monitored during sample analysis (in-study QC; PK incurred-sample reanalysis), establishing that the PK and immunogenicity conclusions rest on analytically sound data (BIOANALYTICAL-001).

9. Conclusions

The clinical pharmacology of GLPI-103 supports both the once-weekly IV and once-daily oral regimens: a long, albumin-binding-driven half-life; approximately dose-proportional exposure; catabolic elimination with low interaction potential; no clinically relevant intrinsic-factor effects; low, inconsequential immunogenicity; and no QT liability. A defined exposure–response relationship justifies the Phase 3 doses and explains the formulation tolerability gradient, supporting the confirmatory program (PROT-301; CSR-301) and the labeling (USPI/SmPC/KR label).